HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 11 (November)

1. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya.
   Int J Cancer, 122(1): 244-6. [Abstract] [Full-text]
2. G2/M cell cycle arrest in the life cycle of viruses.
   Virology, 368(2): 219-26. [Abstract] [Full-text]
3. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin.
   Virology, 368(2): 322-30. [Abstract] [Full-text]
4. Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.
   Virology, 369(1): 214-25. [Abstract] [Full-text]
5. Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue.
   Virology, 369(1): 55-68. [Abstract] [Full-text]
6. HIV-1 infection of monocytes is directly related to the success of HAART.
   Virology, 369(1): 35-46. [Abstract] [Full-text]
7. Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix.
   Virology, 369(1): 47-54. [Abstract] [Full-text]
8. The association of human immunodeficiency virus infection with spontaneously resolved hepatitis C virus infection and level of viremia among injection drug users.
   Dig Dis Sci, 52(12): 3423-30. [Abstract] [Full-text]
9. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
   J Virol, 81(23): 13235-41. [Abstract] [Full-text]
10. Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen.
    J Virol, 81(23): 13125-34. [Abstract] [Full-text]
11. Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1.
    J Virol, 81(23): 13050-6. [Abstract] [Full-text]
12. A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains.
    J Virol, 81(23): 12946-53. [Abstract] [Full-text]
13. Association of Nef with p21-activated kinase 2 is dispensable for efficient human immunodeficiency virus type 1 replication and cytopathicity in ex vivo-infected human lymphoid tissue.
    J Virol, 81(23): 13005-14. [Abstract] [Full-text]
14. Myristoylation is required for human immunodeficiency virus type 1 Gag-Gag multimerization in mammalian cells.
    J Virol, 81(23): 12899-910. [Abstract] [Full-text]
15. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G.
    J Virol, 81(23): 13112-24. [Abstract] [Full-text]
16. Humanized NOD/SCID/IL2Rgamma(null) mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiency virus type 1 pathogenesis.
    J Virol, 81(23): 13259-64. [Abstract] [Full-text]
17. Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.
    J Virol, 81(23): 13037-49. [Abstract] [Full-text]
18. Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.
    J Infect Dis, 196(11): 1645-53. [Abstract] [Full-text]
19. Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1.
    Nat Rev Microbiol, 5(12): 912-6. [Abstract] [Full-text]
20. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
    Lancet, 370(9600): 1698-705. [Abstract] [Full-text]
21. Comparison of toxicogenomic profiles of two murine strains treated with HIV-1-based vectors for gene therapy.
    Toxicol Appl Pharmacol, 225(2): 189-97. [Abstract] [Full-text]
22. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.
    Virology, 369(2): 245-62. [Abstract] [Full-text]
23. Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.
    Virology, 369(2): 329-39. [Abstract] [Full-text]
24. The Vpu-regulated endocytosis of HIV-1 Gag is clathrin-independent.
    Virology, 369(2): 299-308. [Abstract] [Full-text]
25. Gap junctions mediate human immunodeficiency virus-bystander killing in astrocytes.
    J Neurosci, 27(47): 12844-50. [Abstract] [Full-text]
26. Exophytic ulcerated tumors in HIV patients: diagnostic and therapeutic problems.
    Dermatology, 216(1): 60-3. [Abstract] [Full-text]
27. Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins.
    J Virol, 81(24): 13932-7. [Abstract] [Full-text]
28. Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells.
    J Virol, 81(24): 13938-42. [Abstract] [Full-text]
29. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
    J Virol, 81(24): 13845-51. [Abstract] [Full-text]
30. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses.
    J Virol, 81(24): 13852-64. [Abstract] [Full-text]
31. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.
    J Virol, 81(24): 13346-53. [Abstract] [Full-text]
32. Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection.
    J Virol, 81(24): 13486-98. [Abstract] [Full-text]
33. Human seminal plasma abrogates the capture and transmission of human immunodeficiency virus type 1 to CD4+ T cells mediated by DC-SIGN.
    J Virol, 81(24): 13723-34. [Abstract] [Full-text]
34. Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells.
    J Virol, 81(24): 13916-21. [Abstract] [Full-text]
35. Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.
    J Virol, 81(24): 13598-607. [Abstract] [Full-text]
36. A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infection.
    J Virol, 81(24): 13809-15. [Abstract] [Full-text]
37. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells.
    J Exp Med, 204(12): 2813-24. [Abstract] [Full-text]
38. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes.
    J Exp Med, 204(12): 3027-36. [Abstract] [Full-text]
39. Triple bypass: complicated paths to HIV escape.
    J Exp Med, 204(12): 2785-8. [Abstract] [Full-text]
40. The emergence of HIV/AIDS in the Americas and beyond.
    Proc Natl Acad Sci U S A, 104(47): 18566-70. [Abstract] [Full-text]
41. The design of drugs for HIV and HCV.
    Nat Rev Drug Discov, 6(12): 1001-18. [Abstract] [Full-text]
42. Reverse transcription of the HIV-1 pandemic.
    FASEB J, 21(14): 3795-808. [Abstract] [Full-text]
43. CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression.
    FASEB J, 21(14): 4038-46. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.